Search company, investor...
Stemina Biomarker Discovery company logo

Stemina Biomarker Discovery

stemina.com

Founded Year

2006

Stage

Loan | Alive

Total Raised

$19.78M

Valuation

$0000 

Last Raised

$680K | 3 yrs ago

About Stemina Biomarker Discovery

Stemina Cell Discovery discovers and validates small molecules as biomarkers for high-throughput drug screening and disease diagnostics using an all human system comprised of stem cells and the company's metabolomics platform. Metabolomics aims to enable the discovery of small molecules that can be used as candidate biomarkers of disease and pharmacological efficacy or toxicity. The human embryonic stem cell metabolome is a source of candidate biomarkers to predict, diagnose or measure the progress of disease or toxic response. Stemina aims to provide compound screening and diagnostic development for the pharmaceutical and biotechnology industries and academia under contract services or joint discovery agreements.

Headquarters Location

504 South Rosa Road Suite 150

Madison, Wisconsin, 53719,

United States

608-204-0104

Missing: Stemina Biomarker Discovery's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Stemina Biomarker Discovery's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Stemina Biomarker Discovery

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Stemina Biomarker Discovery is included in 3 Expert Collections, including Regenerative Medicine.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

O

Omics

1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

B

Biopharma Tech

838 items

Stemina Biomarker Discovery Patents

Stemina Biomarker Discovery has filed 1 patent.

The 3 most popular patent topics include:

  • Autism
  • Neurological disorders
  • Pervasive developmental disorders
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/27/2018

3/8/2022

Autism, Psychiatric diagnosis, Mass spectrometry, Pervasive developmental disorders, Neurological disorders

Grant

Application Date

7/27/2018

Grant Date

3/8/2022

Title

Related Topics

Autism, Psychiatric diagnosis, Mass spectrometry, Pervasive developmental disorders, Neurological disorders

Status

Grant

Latest Stemina Biomarker Discovery News

Stemina’s Human Cell-Based devTOX quickPredict Assay Able to Predict Developmental Toxicity Potential of Nicotine-Containing Products

Dec 21, 2020

Stemina’s Human Cell-Based devTOX quickPredict Assay Able to Predict Developmental Toxicity Potential of Nicotine-Containing Products New research study published in the scientific journal Current Research in Toxicology Cell-Based devTOX quickPredict Assay predicts developmental toxicity. New research supports the utility of the devTOX quickPredict (devTOXqP) human induced pluripotent stem cell (iPS)-based assay from Stemina Biomarker Discovery (Stemina) as the first human-based in vitro assay to effectively predict risk to early embryonic development induced by chemical exposure, including that from nicotine-containing products. The new study, “The use of human induced pluripotent stem cells to screen for developmental toxicity potential indicates reduced potential for non-combusted products, when compared to cigarettes,” was published online this week in the journal Current Research in Toxicology by scientists from Stemina Biomarker Discovery, Inc. In this research, a variety of nicotine-containing products – including cigarettes, heated tobacco products, and tobacco-free electronic cigarettes (e-cigarettes) – were tested. Assay results predicted that aerosols from reference cigarettes and a heated tobacco product (HTP) trapped in phosphate buffered saline (PBS) offered significant potential risk for early developmental toxicity, driven largely by cytotoxicity from compounds other than nicotine, while those from a hybrid tobacco-flavored e-cigarette and non-tobacco containing e-cigarettes were not predicted to present the same risk in this assay. Stemina’s devTOXqP is a metabolomics biomarker-based test that assesses developmental toxicity potential based on the iPS cells’ alteration in the ratio of key biomarkers, ornithine and cystine (o/c). In this study, smoke and aerosol from test articles were bubbled into phosphate buffered saline (PBS). iPS cells were exposed to 8 concentrations of bubbled PBS (bPBS). Assay sensitivity was assessed through a spiking study with a known developmental toxicant all-trans24 retinoic acid (ATRA). Elizabeth Donley, JD, MBA, MS, Chief Executive Officer of Stemina, commented, “There is a serious need for rapid, cost-effective, high-throughput screening assays with greater relevance to humans than current animal-based tests. From a methodological standpoint, there is also growing regulatory interest in this specific endpoint, and new assays capable of evaluating developmental toxicity are required. The development and subsequent successful assessment of devTOX quickPredict against a variety of nicotine-containing products represents an important step in demonstrating proof-of-concept for this human-based test.” Until recently, assessing the potential toxicity of such products has required the use of in vivo animal testing. However, animal testing is costly, time-consuming, and often poorly predictive of toxicity in humans. Additionally, several European Union member states have banned the use of animal testing in assessing the relative toxicity of tobacco-related products. “While no single in vitro toxicology assay can cover the entire cycle of embryonic development, the results of this research suggest considerable value for devTOXqP as a rapid, cost-effective test for use in screening the potential toxicity of e-cigarettes and other non-combustible nicotine products,” commented Jessica Palmer, MS, Associate Director of Toxicology at Stemina and co-author on the study. The devTOXqP platform has been successfully used by the U.S. Environmental Protection Agency (EPA) to support their ToxCast and Virtual Tissue Model programs. As part of the EPA’s ToxCast Initiative, 1065 phase I and II compounds have been screened in the devTOXqP assay. Within the screened compounds, 19% were predicted to have the potential to cause developmental toxicity, and when compared to in vivo models, the assay had a 79% to 82% accuracy. Donley concluded, “As the greater use of in vitro assays based on human-derived cells is one of the aims of “Toxicity Testing in the 21st Century,” designed to lead to the reduced use or ultimate replacement of animal testing, we are working with the U.S. EPA and the U.S. Food and Drug Administration (FDA) to embed devTOXqP as a recommended assay in nicotine product safety evaluations.” Source: Company Press Release

Stemina Biomarker Discovery Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Stemina Biomarker Discovery Rank

Stemina Biomarker Discovery Frequently Asked Questions (FAQ)

  • When was Stemina Biomarker Discovery founded?

    Stemina Biomarker Discovery was founded in 2006.

  • Where is Stemina Biomarker Discovery's headquarters?

    Stemina Biomarker Discovery's headquarters is located at 504 South Rosa Road, Madison.

  • What is Stemina Biomarker Discovery's latest funding round?

    Stemina Biomarker Discovery's latest funding round is Loan.

  • How much did Stemina Biomarker Discovery raise?

    Stemina Biomarker Discovery raised a total of $19.78M.

  • Who are the investors of Stemina Biomarker Discovery?

    Investors of Stemina Biomarker Discovery include Paycheck Protection Program, U.S. Department of Health and Human Services, National Institutes of Health, Wisconsin Investment Partners, Nancy Lurie Marks Family Foundation and 7 more.

  • Who are Stemina Biomarker Discovery's competitors?

    Competitors of Stemina Biomarker Discovery include Humanetics, Banyan Biomarkers, Esperance Pharmaceuticals, OncoMed Pharmaceuticals, Gamida Cell, Keystone Nano, KBI Biopharma, ChanTest, Scynexis, iPierian and 26 more.

Compare Stemina Biomarker Discovery to Competitors

I
Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

B
BresaGen

NovoCell, Inc./BresaGen is a stem cell engineering company dedicated to creating, delivering, and commercializing cell and drug therapies to treat diabetes and other chronic diseases. Novocell uses its cell encapsulation technology and expertise in cell implantation to develop a renewable source of specialized cells for the treatment of cellular diseases. Bresagen represents a division of Novocell's research operation.

Regenetech Logo
Regenetech

Regenetech develops and offers intellectual property licenses in the area of Adult Stem Cell Expansion and therapeutic applications of adult stem cells. Regenetech uses a technology discovered by NASA in space experiments for growing three-dimensional (3D) stem cells in a weightless environment.

E
Esperance Pharmaceuticals

Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.

CoImmune Logo
CoImmune

CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.

ReproCELL Logo
ReproCELL

ReproCell is a developer of stem cell technologies. The company develops various products, with an underlying theme that focuses on stem cell technology, to address the needs of researchers and clinicians. The product range encompasses reagents for ES/iPS cells and stem cell-derived functional cells.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.